- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | ACESO LIFE SCI (00474): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| Di | ACESO LIFE SCI (00474): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| Di | ACESO LIFE SCI (00474): INTERIM REPORT 2025 | 1 | HKEx | ||
| 28.11.25 | ACESO LIFE SCI (00474): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2025 | 1 | HKEx | ||
| 25.11.25 | ACESO LIFE SCI (00474): POSITIVE PROFIT ALERT | 1 | HKEx | ||
| 14.11.25 | ACESO LIFE SCI (00474): NOTIFICATION OF BOARD MEETING | - | HKEx | ||
| 28.10.25 | ACESO LIFE SCI (00474): VOLUNTARY ANNOUNCEMENT - FULL REPAYMENT OF OUTSTANDING LOAN OF A COMMERCIAL BANK IN HONG KONG | 2 | HKEx | ||
| ACESO LIFE SCIENCE GROUP Aktie jetzt für 0€ handeln | |||||
| 30.09.25 | ACESO LIFE SCI (00474): QUARTERLY UPDATE ANNOUNCEMENT | - | HKEx | ||
| 17.09.25 | ACESO LIFE SCI (00474): VOLUNTARY ANNOUNCEMENT IN RELATION TO REFINANCING OF FACILITY AGREEMENT | 1 | HKEx | ||
| 16.09.25 | ACESO LIFE SCI (00474): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 16 SEPTEMBER 2025 | - | HKEx | ||
| 05.09.25 | ACESO LIFE SCI (00474): ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2025 - SUPPLEMENTAL ANNOUNCEMENT | 1 | HKEx | ||
| 26.08.25 | ACESO LIFE SCI (00474): FURTHER DELAY IN DESPATCH OF CIRCULAR | - | HKEx | ||
| 07.08.25 | ACESO LIFE SCI (00474): GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES | - | HKEx | ||
| 30.07.25 | ACESO LIFE SCI (00474): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 30.07.25 | ACESO LIFE SCI (00474): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS | - | HKEx | ||
| 30.07.25 | ACESO LIFE SCI (00474): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 30.07.25 | ACESO LIFE SCI (00474): PROXY FORM FOR ANNUAL GENERAL MEETING OR ANY ADJOURNMENT THEREOF | - | HKEx | ||
| 30.07.25 | ACESO LIFE SCI (00474): (1) PROPOSAL INVOLVING GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT ... | 2 | HKEx | ||
| 30.07.25 | ACESO LIFE SCI (00474): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024/25 | 1 | HKEx | ||
| 30.07.25 | ACESO LIFE SCI (00474): ANNUAL REPORT 2024/25 | 1 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HARROW | 49,000 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 6,450 | +1,10 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| LB PHARMACEUTICALS | 22,250 | +3,49 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 16,910 | +0,71 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 78,26 | +3,18 % | H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target | ||
| MILESTONE PHARMACEUTICALS | 2,020 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| LIPOCINE | 8,030 | +22,22 % | Lipocine Inc.: Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone | Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026
Topline results on track for the second quarter of 2026
SALT LAKE CITY... ► Artikel lesen | |
| INTERCURE | 0,910 | -8,36 % | Intercure Ltd. - 6-K, Report of foreign issuer | ||
| INHIBIKASE THERAPEUTICS | 2,050 | +4,06 % | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path | ||
| JOURNEY MEDICAL | 7,710 | +1,18 % | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 5,650 | 0,00 % | NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards | EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 6,770 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,279 | +0,36 % | Reviva Pharmaceuticals: Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum | ||
| OMNIAB | 1,840 | -1,08 % | OmniAb outlines $18M-$22M 2025 revenue guidance while launching OmniUltra and expanding xPloration platform | ||
| VYNE THERAPEUTICS | 0,579 | +2,79 % | VYNE Therapeutics: +167% für den NBC! | Kurz vor Weihnachten ist schon wieder Bescherung im No Brainer Club: VYNE Therapeutics liefert nach einem Top-Deal satte +167% Rendite innerhalb weniger Monate. Die Weihnachtsgeschenke der NBC-Mitglieder... ► Artikel lesen |
Das Unternehmen ACESO LIFE SCIENCE GROUP LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACESO LIFE SCIENCE GROUP LTD finden Sie auf Wallstreet Online.